Wang et al. found that canagliflozin treatment, which blocks SGLT2, increased AMPK activation in thyroid cancer cells, hence reducing the growth of thyroid cancer cells in vitro and in vivo (Wang et al. 2022). This evidence concerns the gene SLC5A2 and thyroid gland carcinoma.